# W2 #5 Acceptance Audit — SemRisk–CM-PharmE Bridge

**Date:** 2026-09-22
**Result:** PASS

## Deliverables
- `cm-pharme-concept-bridge-v0.1.csv`: 16 concept/ownership mapping decisions.
- `cm-pharme-relation-bridge-v0.1.csv`: 8 relation/pattern bridge decisions.
- `cm-pharme-category-preservation-audit.csv`: 12 stereotype/category checks.
- `bounded-pharma-case-v0.1.md`: bounded semantic case.
- `pharma-case-source-standard-traceability.csv`: 8 evidence/standard trace rows.
- `pharma-case-cq-registry.csv`: 8 case-specific conceptual CQs.
- `cm-pharme-release-citation-binding.md`: exact release/publication binding.
- `unresolved-pharma-bridge-register.csv`: 7 governed gaps/findings.
- `g1-w2-pharma-ownership-correction-2026-09-22.md`: historical correction addendum.

## Acceptance checks
- Every mapped CM-PharmE entity uses an exact `CMPE-C*` identifier from frozen v1.0.0.
- External semantic owner and version are explicit.
- Kind/role/relator/mode/perdurant stereotypes are preserved in bridge use.
- No mapping uses lexical similarity as equivalence.
- No `owl:equivalentClass` assertion is authorized.
- Pharma case uses existing CM-PharmE concepts and SemRisk risk semantics without creating one-off Core concepts.
- ICH Q9(R1), Pharma literature and qualified dataset roles are traceable.
- Dataset selection is subordinate to semantic/evidence-role controls and can change without redefining the case.
- Case-specific CQs inherit #7 semantic intent and remain implementation-independent.
- No unresolved Critical bridge/category conflict remains.

## Material correction found by #5
`Active Pharmaceutical Ingredient / API / INN` is **not** in CM-PharmE v1.0.0. Earlier SemRisk artifacts that attributed API ownership to CM-PharmE were corrected in current W2 registries. The source term remains preserved historically, while current ownership is `UNMAPPED_EXTERNAL_OWNER_TBD`.

## Remaining governed gaps
- API/product terminology owner is unresolved but does not block the conceptual bridge.
- CM-PharmE redistribution/import license policy remains unresolved; bridge/reference use is allowed, import assumption is not.
- DS-004 exact file mapping remains blocked until file/version/license/schema freeze.
- Exact Objective owner remains external Enterprise/EA work, not CM-PharmE.

## Boundary
PASS means the bounded Paper-1 Pharma federation architecture is ready for G2 and later #28 execution. It does not establish all-Pharma/Health validity, file-level dataset mapping or transferability.